NCAM1 and acute myeloid leukemia: Unconventional CD56-CD16+ NK cells which decreased expression of NKG2A/NKp30/NKp46 in AML has been observed, indicating adverse clinical outcome (134, 135) (Figure 2a), and high expression of NKp46 contribute to the prognosis of AML patients after allo-HSCT (135).